
PROF Stock Forecast & Price Target
PROF Analyst Ratings
Bulls say
Profound Medical Corp is strategically positioning itself for growth, anticipating an increase in its US installed base of TULSA-PRO systems from approximately 53 to 75 by the end of 2024, bolstered by a mixed revenue model comprising capital placements and recurring revenue. The upcoming changes to TULSA reimbursement, including the introduction of an ASC code in early 2024 and CPT codes in early 2025, are expected to significantly enhance access to prostate cancer treatments, potentially increasing the installed base substantially. Additionally, advancements in the TULSA-PRO system, notably through recent software enhancements like the “Thermal Boost Pro,” underscore the growing physician comfort with the technology, which reflects positively on the company's long-term utilization growth potential.
Bears say
Profound Medical Corp's reliance on the success of its TULSA-PRO system and associated CAPTAIN study significantly heightens the company's risk profile, as failure in these areas could lead to diminished adoption rates and worsening reimbursement prospects. The company's single-technology focus further exacerbates this risk, as an ineffective sales strategy could result in stalled or declining revenue growth. Additionally, adverse clinical data or negative recommendations from medical societies could severely impact the product's market acceptance and overall commercial potential amidst a challenging funding and valuation environment in the MedTech sector.
This aggregate rating is based on analysts' research of Profound Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
PROF Analyst Forecast & Price Prediction
Start investing in PROF
Order type
Buy in
Order amount
Est. shares
0 shares